Analysts expect Akebia Therapeutics, Inc. to report revenue of 49.33 M for Q3 26, against a range of 44.63 M to 54.03 M. The most recent reported quarter, Q2 26, came in at 49.13 M, a 3.7% miss against the 51.00 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 37.43 M | 46.50 M | 57.34 M | 62.47 M | 58.77 M | 57.62 M | 53.54 M | 49.13 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 50.31 M | 39.79 M | 46.34 M | 50.34 M | 57.72 M | 46.34 M | 58.05 M | 55.59 M | 54.03 M | 48.87 M | 29.05 M | 32.38 M | 40.98 M | 42.18 M | 40.42 M | 43.46 M | ||||||||||
| Low Estimate | 43.78 M | 33.33 M | 40.48 M | 42.02 M | 53.63 M | 42.34 M | 51.29 M | 46.41 M | 44.63 M | 41.72 M | 26.58 M | 27.05 M | 34.75 M | 37.23 M | 35.04 M | 35.72 M | ||||||||||
| Consensus Estimate | 47.04 M | 36.56 M | 43.41 M | 46.18 M | 55.67 M | 44.34 M | 54.67 M | 51.00 M | 49.33 M | 45.29 M | 27.81 M | 29.71 M | 37.87 M | 39.70 M | 37.73 M | 39.59 M |
Analysts expect Akebia Therapeutics, Inc. to report earnings per share of -0.04 for Q3 26, against a range of -0.04 to -0.04. The most recent reported quarter, Q2 26, came in at -0.03, a 25.0% beat against the -0.04 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.10 | -0.10 | 0.03 | 0.00 | 0.00 | -0.05 | -0.03 | -0.03 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.06 | -0.07 | -0.04 | -0.02 | -0.01 | -0.04 | -0.03 | -0.04 | -0.04 | -0.04 | -0.10 | -0.09 | -0.07 | -0.07 | -0.05 | -0.06 | ||||||||||
| Low Estimate | -0.06 | -0.07 | -0.04 | -0.02 | -0.01 | -0.04 | -0.03 | -0.04 | -0.04 | -0.04 | -0.10 | -0.09 | -0.07 | -0.07 | -0.05 | -0.06 | ||||||||||
| Consensus Estimate | -0.06 | -0.07 | -0.04 | -0.02 | -0.01 | -0.04 | -0.03 | -0.04 | -0.04 | -0.04 | -0.10 | -0.09 | -0.07 | -0.07 | -0.05 | -0.06 |
Pull Wall Street consensus for Akebia Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AKBA&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AKBA", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AKBA&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();